People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Flexion Therapeutics Inc | — | Biotechnology | Series B | $40.0M | $793.8M | 2009 |
| Adipo Therapeutics, Llc | — | Biotechnology | Series A | $6.0M | $20.5M | 2024 |
MICHAEL CLAYMAN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MICHAEL CLAYMAN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| Heath Lukatch | 1 | 10 |
| BRADLEY BOLZON | 1 | 10 |
| Elaine Jones | 1 | 6 |
| SAMUEL COLELLA | 1 | 3 |
| Arthur Fratamico | 1 | 2 |
| NEIL BODICK | 1 | 2 |
| Alan Milinazzo | 1 | 2 |
| Meng Deng | 1 | 1 |
| RAFAELE TORDJMAN | 1 | 1 |
| Patrick Mahaffy | 1 | 1 |
| Keith Johns | 1 | 1 |
| Karen Wurster | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.